Paul M. O’Byrne, MB, FRCP(C), FRSC
McMaster University, Hamilton, ON
This presentation will review the evidence that led to the Canadian Thoracic Society changing the guideline recommendations for the management of mild-to-moderate asthma; particularly in relation to the use of an anti-inflammatory reliever. In addition, the use of biologics for the management of asthma will be reviewed, with specific reference to the selection of appropriate patients who are likely to benefit from the initiation of these treatments.
Learning Objectives:
At the end of this presentation, attendees will be able to:
- Understand the quality of evidence and rationale for the changes in guideline-recommended treatment for mild asthma;
- Identify patients with severe asthma who would benefit from a biologic treatment; and
- Distinguish the differences in the potential benefits from the current biologics available to treat severe asthma.
CanMEDS Roles Addressed: Collaborator, Communicator, Health Advocate, Medical Expert, Scholar
